CardioQ Product Endorsement

Deltex Medical Group PLC
21 November 2007



                            Deltex Medical Group plc

UCLH and Guys & St Thomas's hospitals use CardioQ(TM)to improve surgical 
outcomes


21 November 2007 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, notes that two major London teaching hospitals
have published initial results from introducing a new approach to major surgery
including routine use of the CardioQ.

In an article published in Health Director this week Mr Al Windsor, a senior
consultant colorectal surgeon at University College London Hospital (UCLH)
reports on the early implementation of the Enhanced Surgical Treatment and
Recovery Programme ESTReP at UCLH and Guys and St Thomas's hospitals. ESTReP,
which requires the use of the CardioQ during surgery, was jointly developed by
Mr Windsor with Mr Andrew Williams, a consultant colorectal surgeon at Guys and
St Thomas's.

Mr Windsor states in respect of both Trusts that:

'There are improved outcomes for patients, with reduced morbidity rates, fewer
complications and rapid recovery. Length of stay has been reduced from
approximately 9-10 days per patient to just 6 days.'

With regard to Mr Windsor's hope that ESTReP will be adopted in other types of
surgery at UCLH, he goes on to say:

'Our hepatic surgery colleagues are interested, and the vascular team is looking
at how it might apply to their patients. There's no reason why it can't be
rolled out across the board.'

Deltex Medical's Chief Executive, Andy Hill commented:

'UCLH and Guys and St Thomas's are two of the UK's leading teaching hospitals
and amongst the first hospitals in the world to formalise routine use of the
CardioQ during surgery.

'These excellent results should only encourage other hospitals to follow in
their footsteps. We are already aware of a number of hospitals, both in the UK
and overseas, which have been watching closely progress with ESTReP at UCLH and
Guys and St Thomas's.'


For further information, please contact:-

Deltex Medical Group plc                         01243 774 837

Nigel Keen, Chairman                             [e-mail]
Andy Hill, Chief Executive                       [e-mail]
Ewan Phillips, Finance Director                  [e-mail]


Gavin Anderson & Company                         020 7554 1400

Deborah Walter                                   [e-mail]
Robert Speed                                     [e-mail]


Charles Stanley Securities                       020 7149 6457
Philip Davies                                    [e-mail]
Russell Cook                                     [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM)monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •    Validated the results of the Monitor against known standards for
        measuring cardiac output, demonstrating that the technology works

   •    Proved that the CardioQ works in a wide range of surgical procedures

   •    Demonstrated that the Company's technology provides significant health
        and economic benefits by helping to reduce post-operative complications 
        and length of hospital stays by an average of 30 to 40 per cent for a 
        wide range of patients.

The SupraQ(TM)is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange